DekaBank Deutsche Girozentrale increased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 71.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 227,947 shares of the biopharmaceutical company’s stock after purchasing an additional 94,906 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Alexion Pharmaceuticals were worth $35,735,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GMT Capital Corp acquired a new position in shares of Alexion Pharmaceuticals during the 4th quarter worth about $10,687,000. 9258 Wealth Management LLC raised its holdings in Alexion Pharmaceuticals by 4.1% in the 4th quarter. 9258 Wealth Management LLC now owns 5,650 shares of the biopharmaceutical company’s stock valued at $883,000 after acquiring an additional 222 shares during the last quarter. Varma Mutual Pension Insurance Co acquired a new stake in Alexion Pharmaceuticals in the 4th quarter valued at about $2,343,000. Magnetar Financial LLC acquired a new stake in Alexion Pharmaceuticals in the 4th quarter valued at about $184,465,000. Finally, Dupont Capital Management Corp raised its holdings in Alexion Pharmaceuticals by 84.2% in the 4th quarter. Dupont Capital Management Corp now owns 21,685 shares of the biopharmaceutical company’s stock valued at $3,388,000 after acquiring an additional 9,912 shares during the last quarter. Hedge funds and other institutional investors own 87.27% of the company’s stock.
ALXN has been the subject of several analyst reports. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reissued a “neutral” rating and issued a $175.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 15th. SVB Leerink reissued a “market perform” rating and issued a $156.00 price target (down previously from $196.00) on shares of Alexion Pharmaceuticals in a research note on Monday, March 29th. Roth Capital increased their price target on shares of Alexion Pharmaceuticals from $50.00 to $73.00 in a research note on Tuesday, December 15th. Raymond James cut shares of Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, January 8th. Finally, Piper Sandler cut shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, February 4th. Eighteen analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $151.83.
Shares of ALXN stock opened at $152.35 on Thursday. The company has a quick ratio of 3.26, a current ratio of 3.81 and a debt-to-equity ratio of 0.22. Alexion Pharmaceuticals, Inc. has a 52 week low of $94.23 and a 52 week high of $162.60. The stock has a market capitalization of $33.49 billion, a PE ratio of 35.60, a P/E/G ratio of 0.75 and a beta of 1.33. The firm has a 50 day moving average of $152.91 and a two-hundred day moving average of $140.23.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $2.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.56 by $0.40. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same quarter last year, the company posted $2.71 EPS. The firm’s revenue was up 15.0% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals, Inc. will post 11.14 EPS for the current fiscal year.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Featured Story: How does quantitative easing work?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.